TJPC: Received the approval notice for the listing application of chemical raw materials

TJPC announced that it recently received the "Approval Notice for the Market Application of Chemical Raw Materials" for difluprednate issued by the National Medical Products Administration. Difluprednate is a topical corticosteroid that can inhibit inflammatory responses caused by various irritants. The main formulation available in the market is eye drops, primarily used for treating inflammation and pain related to eye surgeries. According to the IQVIA database, the global sales of difluprednate formulations are projected to be USD 49 million and USD 41 million in 2023 and 2024, respectively